|
1
|
Symmans WF, Yau C, Chen YY, Datnow B, Wei S, Feldman MD, Ritter J, Duan X, Chen B, Tickman R, Sattar H, Magliocco AM, Kallakury B, Troxell M, Asare S, Liu MC, DeMichele A, Yee D, Berry DA, Esserman L. Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.520] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | - Shi Wei
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL
| | | | - Jon Ritter
- University of Minnesota, Minneapolis, MN
| | | | | | | | - Husain Sattar
- The University of Chicago Medical Center, Chicago, IL
| | | | | | | | - Smita Asare
- Quantum Leap Health Care Collaborative, San Francisco, CA
| | | | | | - Douglas Yee
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN
| | - Donald A. Berry
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Laura Esserman
- University of California, San Francisco, San Francisco, CA
| | | |
Collapse
|